Search Clinical Trials
Sponsor Condition of Interest |
---|
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
RTI International
Sickle Cell Disease
The goal of this observational study is to help us understand more about the best ways to
help individuals living with Sickle Cell Disease (SCD) get the best care. The main
question it aims to answer is: How to find individuals unaffiliated from SCD specialist
care use three distinct pathways? Once... expand
The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assessment survey which will cover areas such as previous and current treatment, clinic and hospital experience, pain, and quality of life. Participants will also be given the option of participation in a 1-hour long interview how they feel about treatment for sickle cell disease including clinic experience, pain, and quality of life? Type: Observational Start Date: Jun 2023 |
Acceptance and Commitment Therapy for Depressed People With Spinal Cord Injuries
University of Alabama at Birmingham
Depression
Spinal Cord Injuries
Living with spinal cord injury (SCI) can have a significant negative impact on an
individual's mental health and restrict participation in personally valued activities and
roles. Acceptance and commitment therapy (ACT) is an evidence-based approach that can
lessen symptoms of mental health disorders... expand
Living with spinal cord injury (SCI) can have a significant negative impact on an individual's mental health and restrict participation in personally valued activities and roles. Acceptance and commitment therapy (ACT) is an evidence-based approach that can lessen symptoms of mental health disorders (e.g., depressive symptoms) and improve quality of life through mindfulness and acceptance processes and behavior change processes for valued living. Evidence for ACT for individuals living with SCI, however, is limited to a very few studies that involved in-person group-based ACT and did not focus on depressed individuals with SCI. The primary goal of this study is to evaluate the effects of an 8-week videoconferencing ACT program on improving mental health outcomes in depressed individuals living with SCI. The primary hypotheses are that the ACT group will show improvements in depressive symptoms at posttest and 2-month follow-up compared to the wait-list control group. Investigators will invite 120 individuals living with SCI and reporting depressive symptoms and randomly assign them to either the ACT group or the wait-list control group. The ACT group will receive eight weekly individual ACT sessions guided by a coach through videoconferencing with a booster session at 1-month follow-up. The wait-list control group will continue his or her own care as usual during the study period and have the option to receive eight individual ACT sessions after study participation ends. Data will be collected at pretest, posttest, and 2-month follow-up and compared between the ACT group and the control group over time. About 40% of individuals living with SCI report depressive symptoms and other mental health symptoms, and mental health disorders following SCI are associated with negative long-term outcomes. Managing uncomfortable or painful thoughts and emotions arising from functional limitations and accepting changed lives while moving forward for valued living through ACT skill practice will help individuals with SCI alleviate symptoms of mental health conditions, promote engagement in personally valued activities, and improve quality of life. Type: Interventional Start Date: Apr 2024 |
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype
Glioblastoma
Glioblastoma Multiforme
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
GBM
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in
combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to
evaluate safety and tolerability of this combination at that dose. expand
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose. Type: Interventional Start Date: Jul 2023 |
Dissemination and Implementation of the Bright Bodies Intervention for Childhood Obesity
Yale University
Obesity, Childhood
This study will evaluate the effectiveness of the Bright Bodies intervention in improving
body mass index (BMI) among 7-13 year-old children with obesity simultaneously with the
impact of the implementation strategy on adoption, reach, fidelity, cost, and maintenance
of the intervention in three heterogenous... expand
This study will evaluate the effectiveness of the Bright Bodies intervention in improving body mass index (BMI) among 7-13 year-old children with obesity simultaneously with the impact of the implementation strategy on adoption, reach, fidelity, cost, and maintenance of the intervention in three heterogenous settings serving patients disproportionately affected by obesity. Type: Interventional Start Date: Oct 2022 |
REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval...
Duke University
COVID-19
Critical Illness
ICU Acquired Weakness
PICS
Cardiorespiratory Fitness
Multicenter, prospective, randomized controlled trial providing mobile health supported
physical rehabilitation to 120 patients who have been critically ill with COVID-19 and
who complete at least one exercise session. expand
Multicenter, prospective, randomized controlled trial providing mobile health supported physical rehabilitation to 120 patients who have been critically ill with COVID-19 and who complete at least one exercise session. Type: Interventional Start Date: Feb 2023 |
Coaching Dementia Caregivers to Master Care-Resistant Behavior
University of Alabama at Birmingham
Care-resistant Behavior
Dementia
266 family caregivers will be randomly assigned to either immediate intervention or
delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of
daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They
will complete 3 rounds of 3-week daily... expand
266 family caregivers will be randomly assigned to either immediate intervention or delayed intervention groups. All caregivers will complete baseline surveys and 3 weeks of daily diaries. The immediate intervention group will receive 12 weeks of CuRB-IT. They will complete 3 rounds of 3-week daily diaries followed by an intermittent survey at 12 week intervals for the next 33 weeks. The delayed intervention group will receive 12 weeks of attention, complete 1 round of 3-week daily diaries followed by an intermittent survey, then complete 12 weeks of CuRB-IT, and complete 2 rounds of 3--week daily diaries followed by an intermittent survey at 12-week intervals for the next 18 weeks. Type: Interventional Start Date: Apr 2023 |
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas...
University of California, San Francisco
Recurrent World Health Organization (WHO) Grade II Glioma
Low-grade Glioma
High Grade Glioma
This phase I trial studies the side effects and best dose of trametinib and everolimus in
treating pediatric and young adult patients with gliomas that have come back (recurrent).
Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth.
Everolimus is a drug that may... expand
This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone. Type: Interventional Start Date: Dec 2020 |
Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors
University of Alabama at Birmingham
Breast Cancer
Gut Microbiome
Exercise
Fatigue
The primary goal of this project is to determine the effects of exercise on the gut
microbiome in breast cancer survivors and determine how these changes may relate to
psychosocial symptoms such as fatigue. expand
The primary goal of this project is to determine the effects of exercise on the gut microbiome in breast cancer survivors and determine how these changes may relate to psychosocial symptoms such as fatigue. Type: Interventional Start Date: Jan 2020 |
Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders
University of Alabama at Birmingham
Movement Disorders
The purpose of this study is to investigate the brain activity associated with motor and
non-motor symptoms of movement disorders, including Parkinson's disease (PD) and
essential tremor. These movement disorders commonly have significant non-motor features,
such as depression, cognitive and memory... expand
The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower processing speeds. The investigators are interested in the brain activity associated with these motor and non-motor symptoms, and propose to investigate changes in brain activity while the investigators perform recordings of the surface and deep structures of the brain, in addition to the typical recordings the investigators perform, during routine deep brain stimulation (DBS) surgery. Type: Interventional Start Date: Sep 2019 |
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory
patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators
hypothesize the drug will decrease pulmonary injury... expand
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug will decrease pulmonary injury due to reactive oxygen species (ROS) generated by NOX enzymes, which are believed to play an important role in the development of IPF. Treatment with GKT137831 could result in significant benefit for a lung disease that has, until now, been almost invariably inexorable. This clinical trial represents the bedside application of a series of NOX translational and basic studies and discoveries, over several years, from the laboratory of Dr. Victor Thannickal. Type: Interventional Start Date: Sep 2020 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
QuantumLeap Healthcare Collaborative
Breast Neoplasms
Breast Cancer
Breast Tumors
Angiosarcoma
TNBC - Triple-Negative Breast Cancer
The purpose of this study is to further advance the ability to practice personalized
medicine by learning which new drug agents are most effective with which types of breast
cancer tumors and by learning more about which early indicators of response (tumor
analysis prior to surgery via magnetic resonance... expand
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success. Type: Interventional Start Date: Mar 2010 |
Sex, Hormones and Identity Affect Nociceptive Expression
University of Alabama at Birmingham
Pain
Gender Identity
The Investigators have recently published on differences in pain sensitivity measures
between cis and trans individuals in the local area. The investigators observed the
anticipated differences in pain sensitivity between CM and CW (CW > CM), but found that
the TW were phenotypically similar to CW... expand
The Investigators have recently published on differences in pain sensitivity measures between cis and trans individuals in the local area. The investigators observed the anticipated differences in pain sensitivity between CM and CW (CW > CM), but found that the TW were phenotypically similar to CW in all measures. However, the investigators did not assess hormone level, nor did the investigators recruit TM participants. Here, with the assistance of two local community group stakeholders the investigators will recruit the following groups: CM, CW, TM+T (currently taking exogenous testosterone), TW+E (exogenous estradiol), TM, and TW (n=20/group). The investigators will use quantitative sensory testing to assess sensitivity to cold, pressure, and heat via standardized protocols. Blood samples will be taken for assessment of stress and reproductive hormone levels, immune cell populations and stimulated cytokine release. Finally, questionnaires will measure pain state, quality of life (QOL), voice QOL, body image, appearance, self-reported health, masculinity/femininity, community connectedness, gender role, sleep, depression, social support, adverse childhood experiences and stigma. Type: Observational Start Date: Mar 2023 |
SPIROMICS Study of Early COPD Progression (SOURCE)
Weill Medical College of Cornell University
COPD, Early-Onset
This is an observational study of 1000 participants to further define the nature of early
chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals.
The study has three main goals:
- To use CT scan imaging to identify which smokers will develop COPD.
- To identify biomarkers... expand
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: - To use CT scan imaging to identify which smokers will develop COPD. - To identify biomarkers predictive of smokers that will develop COPD. - To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related questionnaires assessing medical history, smoke exposure and use, medication use, social and behavioral health, pulmonary symptoms, food frequency, and will provide nasal swab, blood, stool, and urine samples, pulmonary function testing to determine function, sputum induction to provide a sputum sample for airway biospecimen analysis, and CT imaging of the lungs. Type: Observational Start Date: Sep 2021 |
Risk Underlying Rural Areas Longitudinal Cohort Study (RURAL) Heart and Lung Study
The University of Texas Health Science Center at San Antonio
Rural Health
Pulmonary Disease
Heart Diseases
The University of Texas Health Science Center at San Antonio (UTHSCSA) will serve as the
site for the RURAL Study Coordinating Center, led by PI Vasan Ramachandran, MD.
The primary function of the Study Coordinating Center (SCC) is to serve as an
administrative liaison between all of the RURAL study's... expand
The University of Texas Health Science Center at San Antonio (UTHSCSA) will serve as the site for the RURAL Study Coordinating Center, led by PI Vasan Ramachandran, MD. The primary function of the Study Coordinating Center (SCC) is to serve as an administrative liaison between all of the RURAL study's cores. The SCC schedules, facilitates, and hosts, all RURAL meetings including preparation for Observational Study Monitoring Board (OSMB) meetings, and maintains direct communication with the study's program officers at NHLBI. The SCC monitors the overall progress of RURAL and keeps all RURAL cores abreast of study updates through meetings, emails, newsletters. It also maintains the official RURAL website and serves as an administrator for investigators seeking to collaborate with RURAL through the submission of Ancillary Studies. The SCC will have no direct interaction with any participants, nor will it have access to identifiable data. Type: Observational Start Date: Jan 2021 |
Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers
University of Alabama at Birmingham
Kidney Stone
This protocol seeks to determine if weight reduction with the Optifast VLCD program leads
to reduced contribution of endogenous oxalate synthesis to the urinary oxalate pool in
obese calcium oxalate stone formers. expand
This protocol seeks to determine if weight reduction with the Optifast VLCD program leads to reduced contribution of endogenous oxalate synthesis to the urinary oxalate pool in obese calcium oxalate stone formers. Type: Interventional Start Date: Dec 2021 |
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
University of Alabama at Birmingham
COVID-19 Disease
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial
permeability and contribute to multi-organ injury in patients with COVID-19 disease and
to correlate the levels of these mediators with disease outcomes such as ICU admission,
length of ventilatory support, respiratory... expand
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death. Type: Observational Start Date: May 2020 |
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
National Cancer Institute (NCI)
Stage III Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given
together with or without sargramostim and to see how well they work in treating patients
with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may
have spread from where it first... expand
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Type: Interventional Start Date: Nov 2015 |
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic,...
Tvardi Therapeutics, Incorporated
Hepatocellular Carcinoma
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability
of TTI-101 orally administered as a single agent to participants with locally advanced or
metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum
tolerated dose (MTD) and/or recommended... expand
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 as a single agent in participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohort A Phase 2 are to assess response, progression, survival, and pharmacokinetics. The primary objectives of Cohorts B and C Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, or unresectable HCC and to determine the MTD and/or RP2D of TTI-101 when used in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C). The primary objectives of Cohorts B and C Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 in combination with pembrolizumab therapy (Cohort B) and in combination with atezolizumab and bevacizumab therapy (Cohort C) to participants with locally advanced or metastatic, and unresectable HCC. The secondary objectives of Cohorts B and C Phase 2 are to assess response, progression, survival, and pharmacokinetics. Type: Interventional Start Date: Mar 2023 |
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
University of Alabama at Birmingham
Multiple Myeloma
Similar to the paradigm established in other hematologic malignancies that are considered
curable, the achievement of MRD(-) status is necessary for long term disease control in
MM. The fact that the majority of patients remain MRD (+) after induction therapy and
AHCT points to the opportunity to... expand
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-). Type: Interventional Start Date: Jan 2023 |
STROKE STAT (Stroke Severity-based Triage to Accelerate Treatment)
University of Alabama at Birmingham
Stroke
Acute stroke systems of care should emulate trauma systems which deliver the full range
of care to all injured patients by means of organized, coordinated efforts in defined
geographic areas. Just as trauma systems have proven ability to save lives of the most
severely injured patients, clinicians... expand
Acute stroke systems of care should emulate trauma systems which deliver the full range of care to all injured patients by means of organized, coordinated efforts in defined geographic areas. Just as trauma systems have proven ability to save lives of the most severely injured patients, clinicians should have a stroke system able to provide care to patients with the most severe strokes. The most severe type of acute ischemic stroke is due to proximal large vessel occlusion (LVO). Mechanical thrombectomy (MT) offers an extraordinary potential to improve the outcome of patients with LVO. Unfortunately, in part because MT is available only at advanced stroke centers, only a minority of patients with LVO are treated with MT, and there are racial, socioeconomic, and rural disparities in access to MT. Based on the success of trauma systems and our prior collaboration, the Alabama Department of Public Health (ADPH) is planning a five-year statewide quality improvement initiative of trauma communications center (TCC) coordinated severity-based stroke triage (SBST) which aims to transform the fragmented acute stroke care system by coordinating prehospital and inter-facility emergency stroke care. Type: Observational Start Date: Apr 2022 |
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell...
SWOG Cancer Research Network
Recurrent T Acute Lymphoblastic Leukemia
Refractory T Acute Lymphoblastic Leukemia
This phase II trial studies how well OBI-3424 works in treating patients with T-cell
acute lymphoblastic leukemia that has come back (relapsed) or does not response to
treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different
ways to stop the growth of cancer cells, either... expand
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body. Type: Interventional Start Date: Feb 2021 |
Molecular Transducers of Physical Activity Consortium
Wake Forest University Health Sciences
Physical Activity
The goal of the Molecular Transducers of Physical Activity Consortium (MoTrPAC) is to
assess molecular changes that occur in response to physical activity (PA). To achieve
this aim, a mechanistic randomized controlled trial (RCT) is conducted, in which adult
study participants are randomized to endurance... expand
The goal of the Molecular Transducers of Physical Activity Consortium (MoTrPAC) is to assess molecular changes that occur in response to physical activity (PA). To achieve this aim, a mechanistic randomized controlled trial (RCT) is conducted, in which adult study participants are randomized to endurance exercise (EE) training, resistance exercise (RE) training, or no exercise Control for a period of approximately 12 weeks. The overarching hypothesis is that there are discoverable molecular transducers that communicate and coordinate the effects of exercise on cells, tissues, and organs, which may initiate processes ultimately leading to the health benefits of exercise. Because this is a mechanistic trial, the main goal is not a single health-related outcome. Rather, the goal is to generate a resource leading to the generation of a map of the molecular responses to exercise that will be used by the Consortium and by the scientific community at large to generate hypotheses for future investigations of the health benefits of PA. Type: Interventional Start Date: Aug 2019 |
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid...
Caribou Biosciences, Inc.
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets
C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety,
preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults
with acute myeloid leukemia (AML) that has... expand
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not respond or is no longer responding to other treatment (refractory). Participants must have received at least 1 but not more than 3 prior lines of treatment for AML . Type: Interventional Start Date: Feb 2024 |
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
Acute Myeloid Leukemia
B-cell Acute Lymphoblastic Leukemia
High-risk Myelodysplastic Syndrome
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum
optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in
subjects with advanced CD123+ hematologic malignancies expand
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies Type: Interventional Start Date: Sep 2023 |
Evaluation of the "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction
Blue Halo Biomedical, LLC
Urinary Retention
The Investigators will study a device for men in urinary retention secondary to Benign
Prostatic Hyperplasia, BPH ,who are catheter dependent or who have a Post Void Residual >
350cc. The hypothesis is that the device will allow these participants to return to
volitional voiding with a Post Void Residual... expand
The Investigators will study a device for men in urinary retention secondary to Benign Prostatic Hyperplasia, BPH ,who are catheter dependent or who have a Post Void Residual > 350cc. The hypothesis is that the device will allow these participants to return to volitional voiding with a Post Void Residual <75 cc. Type: Interventional Start Date: Aug 2022 |
- Previous
- Next